icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022
Back grey_arrow_rt.gif
Improved recurrence-free survival rates in patients with
HCV-related hepatocellular carcinoma and sustained virological
response to direct-acting antivirals

  EASL 2022 June 22-26 London
Cristina-Maria Muzica1, Anca Trifan1, Laura Huiban1, Oana Stoica1, Irina Girleanu1, Stefan Chiriac1, Ana-Maria Singeap1, Camelia Cojocariu1, Tudor Cuciureanu1, Sebastian Zenovia1, Robert Nastasa1, Carol Stanciu1. 1Grigore T. Popa University of Medicine and Pharmacy, Gastroenterology, Iasi, Romania


Background and aims: Despite the high efficacy of direct-acting antivirals (DAAs) in chronic HCV infection, a more aggressive pattern of hepatocellular carcinoma (HCC) in patients previously treated with DAAs, has been reported. Tumor aggression in HCV-related HCC after DAAs has been linked to impaired outcome. On this basis, we aimed to assess the pattern of HCC and survival rates in patients previously treated with DAAs therapy.